THU0302 Survival of disease-modifying drugs (DMARD) in patients with recent diagnosis of psoriatic arthritis in daily clinical practice

Simple item page
dc.contributor.authorD. Freites
dc.contributor.authorLeticia León
dc.contributor.authorZulema Rosales
dc.contributor.authorJ. Font
dc.contributor.authorCristina Lajas
dc.contributor.authorEsperanza Pato
dc.contributor.authorLuis Rodríguez‐Rodríguez
dc.contributor.authorBenjamín Fernández‐Gutiérrez
dc.contributor.authorJuan Ángel Jover
dc.contributor.authorLydia Abásolo
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T17:56:30Z
dc.date.available2026-03-22T17:56:30Z
dc.date.issued2018
dc.identifier.doi10.1136/annrheumdis-2018-eular.2508
dc.identifier.urihttps://doi.org/10.1136/annrheumdis-2018-eular.2508
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/67162
dc.language.isoen
dc.publisherBMJ
dc.relation.ispartofAnnals of the Rheumatic Diseases
dc.sourceUniversidad Complutense de Madrid
dc.subjectMedicine
dc.subjectPsoriatic arthritis
dc.subjectDisease
dc.subjectClinical Practice
dc.subjectInternal medicine
dc.subjectPsoriasis
dc.subjectDermatology
dc.subjectIntensive care medicine
dc.titleTHU0302 Survival of disease-modifying drugs (DMARD) in patients with recent diagnosis of psoriatic arthritis in daily clinical practice
dc.typearticle

Files

Collections

Artículo Científico Publicado